The global schizophrenia drugs market revenue was around US$ 7.57 billion in 2022 and is estimated to reach US$ 12.57 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.8% during the forecast period from 2023 to 2031.
Schizophrenia is a chronic, severe mental disease that impacts the way a person acts, thinks, perceives reality, expresses emotions, and relates to others. Schizophrenia can be the most persistent and incapacitating mental disorder, although being less frequent than other severe mental illnesses.
Market Driving Factors
The surge in the prevalence of mental disturbances & schizophrenia and the increase in awareness about mental health is estimated to drive the market growth. This is due to the increase in mental health awareness programs by non-government and government organizations. For instance, in May 2023, the U.S. Department of Health and Human Services (HHS) celebrated Mental Health Awareness Month, to raise awareness about mental health. As a result, these awareness programs encourage mental health and aid in offering treatment of mental health illnesses.
The surging prevalence of schizophrenia and associated disorders along with the increasing geriatric population, who are more sensitive to late-onset schizophrenia, is the main factor boosting the market. For instance, in January 2022, according to the World Health Organization, schizophrenia affects 24 million individuals worldwide. Furthermore, this number is likely to continue to rise, along with the growth in the aging population.
Adverse effects of the medications include weight gain, sleeplessness, dry mouth, sleepiness, and other side effects. Thus, this factor hampers the market growth.
Regional Analysis
North America dominated the market in terms of revenue growth and is estimated to continue its dominance. This can be majorly attributed to the immediate adoption of cutting-edge schizophrenia drugs across the region. Furthermore, surged awareness, raised demand for efficient drugs, and a growing number of schizophrenic patients are also estimated to drive the market in the region.
Asia Pacific is estimated to dominate the market in terms of the highest growth. This is mainly due to the surging awareness and rise in focus towards mental health. In addition, healthcare experts and companies from China, India, Japan, and the rest of the region are taking an interest in the effective administration of schizophrenia therapeutics and also concentrating on the new product launches in the region.
Segmentation Insights
Distribution Channel Insight
The hospital pharmacies segment dominates the market in terms of the largest shares. This is primarily owing to the significant growth likely to affect people with schizophrenia, who often need hospitalization during the treatment at some point. As a result, the patients obtain the medicines directly from the hospital pharmacies.
The retail pharmacies segment dominated the market in terms of the largest revenue and is expected to maintain its dominance. This can be attributed to the raised in the number of retail pharmacies and the surged in demand for oral anti-psychotic drugs.
Therapeutic Class Insight
The second-generation antipsychotics segment dominates the market in terms of the largest revenue. This is mainly owing to the increasing usage in the treatment of schizophrenia owing to its high efficacy over first-generation drugs. Furthermore, fewer side effects compared to first-generation antipsychotics are also estimated to boost the segment growth.
Prominent Companies
Segmentation Outline
The global schizophrenia drugs market segmentation focuses on the Treatment, Distribution Channel, Therapeutic Class, and Region.
By Treatment
By Distribution Channel
By Therapeutic Class
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL SCHIZOPHRENIA DRUGS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: SCHIZOPHRENIA DRUGS MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL SCHIZOPHRENIA DRUGS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT
5.1 OVERVIEW
5.2 ORAL
5.3 INJECTABLE
6 GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1 OVERVIEW
6.2 HOSPITAL PHARMACIES
6.3 RETAIL PHARMACIES
6.4 ONLINE PHARMACIES
7 GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS
7.1 OVERVIEW
7.2 SECOND GENERATION
7.3 THIRD GENERATION
7.4 OTHERS
8 GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL SCHIZOPHRENIA DRUGS MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 NOVARTIS AG
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 MINERVA NEUROSCIENCES
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 ABBVIE
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 TAKEDA PHARMACEUTICALS
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 SUMITOMO DAINIPPON
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 MERCK KGAA
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 VANDA PHARMACEUTICALS
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 BRISTOL MYERS SQUIBB
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 ELI LILLY
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 JOHNSON & JOHNSON
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.11 GLAXOSMITHKLINE
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.12 ALKERMES
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.13 RELIANCE
10.13.1 OVERVIEW
10.13.2 FINANCIAL PERFORMANCE
10.13.3 PRODUCT OUTLOOK
10.13.4 KEY DEVELOPMENTS
10.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.14 PFIZER INC
10.14.1 OVERVIEW
10.14.2 FINANCIAL PERFORMANCE
10.14.3 PRODUCT OUTLOOK
10.14.4 KEY DEVELOPMENTS
10.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.15 ASTRAZENECA
10.15.1 OVERVIEW
10.15.2 FINANCIAL PERFORMANCE
10.15.3 PRODUCT OUTLOOK
10.15.4 KEY DEVELOPMENTS
10.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved